https://www.businesswire.com/news/home/20251119935505/en/Avenzo-Therapeutics-Announces-Appointment-of-Scott-Lipman-as-Chief-Financial-Officer
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
avenzotherapeuticsannouncesappointment
https://www.businesswire.com/news/home/20250522705047/en/Avenzo-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418,...
Avenzo Therapeutics Announces FDA Clearance of IND Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific ADC
investigational new drug
https://www.businesswire.com/news/home/20240326751301/en/Avenzo-Therapeutics-Announces-%24150-Million-Oversubscribed-Financing-To-Advance-Emerging-Oncology-Pipeline
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology...
Avenzo Therapeutics announces the closing of an oversubscribed $150 million Series A-1 financing, bringing total capital raised to $347 million.
150 millionavenzotherapeuticsannounces
https://www.businesswire.com/news/home/20251211085624/en/Avenzo-Therapeutics-Presents-Initial-Results-from-the-Phase-12-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential...
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 SABCS
https://www.biospace.com/press-releases/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-1418-a-potential-best-in-class-novel-egfr-her3-bispecific-antibody-drug-conjugate
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418,...
investigational new drug
https://www.businesswire.com/news/home/20250603522149/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class,...
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate